Alterity Therapeutics Launches Facility to Sell Small Share Parcels

The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).

Alterity Therapeutics has introduced an opt-out unmarketable parcel sale facility for shareholders holding less than A$500 worth of its fully paid ordinary shares, aiming to give these investors a cost-free way to exit positions that might otherwise be uneconomic to trade. The company notes that about 59.2% of its roughly 5,868 shareholders fall into this category, and the initiative is also designed to streamline its share register and reduce the administrative expense of maintaining numerous small holdings.

Shareholders with unmarketable parcels who wish to retain their stakes must submit a Share Retention Form or increase their holdings to a marketable level by the stated deadline, while those taking no action will have their shares sold under the facility. Key dates include a record date of 9 March 2026, dispatch of letters on 12 March 2026, a closing date for retention forms on 24 April 2026, and payment to affected shareholders expected as soon as practicable after 7 May 2026, with the company reserving the right to modify, suspend, or terminate the facility via ASX announcement.

The most recent analyst rating on (AU:ATH) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.

More about Alterity Therapeutics

Alterity Therapeutics Limited is an Australia-based biotechnology company listed on the ASX under the ticker ATH. The company focuses on developing therapeutic treatments, and its ordinary shares are widely held by retail investors, many of whom currently own small, low-value share parcels in the market.

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$76.13M

For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.